DEV

You are viewing our development site. Please share feedback with support@dosevault.ai or on our Discord server. See what is new in the changelog.

DOSEVAULT
Metabolic

Liraglutide

Daily GLP-1 analog; FDA-approved for diabetes (Victoza) and obesity (Saxenda®).

Molecular Profile
linear
31 AA Sequence
CAS
204656-20-2
Mol. weight
3751 g/mol
Formula
C172H265N43O51
Chain length
31 aa
Sequence
palmitoylated GLP-1(7-37) analog
Onset and duration

Appetite or glycemic effects within the first days; full effect accrues over weeks to months alongside titration.

Storage and reconstitution

Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.

Clinical Evidence

What the literature says

Scientific Overview

Liraglutide is a once-daily GLP-1 receptor agonist with 97% homology to native GLP-1 plus a fatty-acid linker for albumin binding. Sold as Victoza (T2DM, 2010) and Saxenda (obesity, 2014) by Novo Nordisk. The LEADER trial showed cardiovascular event reduction in T2DM. Now largely displaced by weekly semaglutide.

Citations (4)

  1. Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trialPubMed
  2. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementPubMed
  3. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical TrialReview
  4. Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trialsReview

Research Guide

How users approach this compound

The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.

Research Protocols

Common Dosages

Obesity

0.6 -> 3.0 mg
Daily SC

“Weekly titration”

Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Key Research Benefits

  • Weight loss ~5-8%
  • HbA1c reduction
  • CV benefit (LEADER trial)

Potential Side Effects

Nausea
Vomiting
Pancreatitis (rare)
Gallbladder events

Labs to monitor

Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.

  • HbA1c: Primary glycemic efficacy marker for incretin therapy.
  • Fasting glucose: Tracks glycemic response and hypoglycemia risk when combined with other agents.
  • Lipid panel / ApoB: Incretin therapy commonly improves atherogenic lipids alongside weight loss.

Dose Calculator

Peptide Reconstitution Calculator

mg

Total amount of peptide in the vial.

mL

Volume of water used to mix.

mcg

Draw to this mark

24 Units

or 0.24 mL on a U-100 syringe

Concentration:2.50 mg/mL
Peptide per Unit:25.00 mcg/unit
*Always double-check your calculations. This tool is for educational purposes only.

Liraglutide by goal

Read Liraglutide's profile filtered through specific research goals.

Liraglutide for Fat Loss

Related Tools

Not medical advice

Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.